Opioid Receptors Influence Ischemia-Reperfusion Injury
Information source: Radboud University
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ischemia-Reperfusion Injury
Intervention: morphine (Drug); naloxone (Drug); Technetium-TC99m-labeled Annexin A5 (Drug); forearm ischemic exercise (Procedure); ten minute forearm ischemia (Procedure)
Phase: N/A
Status: Recruiting
Sponsored by: Radboud University Official(s) and/or principal investigator(s):
Gerard Rongen, MD, Phd, Principal Investigator, Affiliation: Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
Overall contact:
Patrick Meijer, MD, Phone: +31243619967, Email: pmeijer@anes.umcn.nl
Summary
The most powerful protective mechanism against ischemia-reperfusion injury other than rapid
reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the
development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia
resulting in a marked reduction in infarct size. This mechanism can be mimicked by several
pharmacological substances such as adenosine and morphine.
We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a
method in which we can detect ischemia-reperfusion injury in the human forearm by using
Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid
receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic
ischemic preconditioning and that acute ischemic preconditioning can be blocked with the
opioid receptor antagonist naloxon. This study will increase our knowledge about the
mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous
protective mechanism in a clinical setting.
Clinical Details
Official title: Opioid Induced Acute Preconditioning
Study design: Randomized, Double-Blind, Placebo Control, Crossover Assignment
Primary outcome: Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
Healthy male volunteers
Exclusion Criteria:
Exposition to radiation due to imaging techniques in the previous five years
Locations and Contacts
Patrick Meijer, MD, Phone: +31243619967, Email: pmeijer@anes.umcn.nl
Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology, Nijmegen, Gelderland 6500 HB, Netherlands; Recruiting
Patrick Meijer, MD, Phone: +31243619967, Email: pmeijer@anes.umcn.nl
Additional Information
Related publications: Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.
Starting date: January 2005
Last updated: March 15, 2006
|
